Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting in Milan September 28 through October 2, 2026 sets up the September obesity-peptide catalyst calendar and is anchored on the amylin agonist class. AstraZeneca will present Phase 2 APRICUS data (AZD6234 amylin analog monotherapy in obesity) plus the Phase 2b ASCEND readout (AZD6234 plus AZD9550 GLP-1/glucagon dual agonist combination against placebo over 36 weeks, 377 patients). Zealand Pharma and Roche will present petrelintide ZUPREME-2 data (obesity plus type 2 diabetes) with Phase 3 monotherapy initiation planned late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD readout window coincides with Roche's Pharma Day September 28 (updates on petrelintide, enicepatide, HM17321). Ascendis Pharma may also provide TransCon CNP achondroplasia updates. The clustered amylin data will position the class for late-2026 and 2027 regulatory and Phase 3 initiation decisions.
Kailera Therapeutics (NASDAQ: KLRA) holds rights outside Greater China to several Hengrui Pharma obesity drugs. Ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP dual agonist, is in the three-trial global KaiNETIC Phase 3 program, which had enrolled more than 4,700 participants as of August 12, 2026, testing doses up to 10 mg over 76 weeks with data expected in 2028. KAI-7535 (HRS-7535) is a separate drug, a once-daily oral small-molecule GLP-1 receptor agonist, now in a roughly 320-person global Phase 2 trial in the U.S. and Australia with data expected in 2027; Kailera's GLP-1/GIP/glucagon triple agonist is a third drug, HRS-4729.
Alteogen (KOSDAQ: 196170) announced Wednesday September 2, 2026 an option and license agreement with Novartis (NYSE: NVS) for the development and commercialization of subcutaneous formulations of multiple Novartis products using Alteogen's ALT-B4 (berahyaluronidase alfa) enabled by the proprietary Hybrozyme technology. Terms: up to $3.22 billion in aggregate potential value including option exercise fees, development and commercial milestone payments, plus royalties on net sales. ALT-B4 temporarily depolymerizes hyaluronan in the extracellular matrix, enabling co-administered biologics to disperse and absorb subcutaneously rather than requiring intravenous infusion. The transaction is Alteogen's fourth Hybrozyme deal in 2026 following prior agreements with Merck KGaA, Sanofi, and one undisclosed global pharma. The technology approach mirrors Halozyme Therapeutics's ENHANZE platform (used in Roche's SC Herceptin, Rituxan, and Ocrevus, plus Bristol Myers Squibb's SC Opdivo and Johnson & Johnson's SC Darzalex), and the SC-conversion category has become an anchor commercial strategy for pharma companies looking to extend patent life and improve patient convenience on established IV biologics.
Superluminal Medicines announced Thursday September 3, 2026 an oversubscribed $60 million Series B financing round led by BVF Partners with participation from Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. Proceeds will advance the company's lead clinical program (a selective, biased MC4R agonist) into Phase 1 for rare genetic forms of obesity including Bardet-Biedl syndrome (BBS) and hypothalamic obesity, targeting Phase 1 initiation by end of 2026. Superluminal's technology platform uses AI plus GPCR-structural chemistry to design biased agonists with reduced off-target signaling. The MC4R agonist positioning is directly against Rhythm Pharmaceuticals's Imcivree (setmelanotide, the currently-approved MC4R agonist peptide for BBS and hypothalamic obesity) — a small-molecule alternative would have oral bioavailability advantages plus different tolerability profile. Eli Lilly's investor participation extends Lilly's obesity-adjacent equity portfolio.
QL Biopharm (Beijing, Zhitai Biopharmaceutical) closed a Series C financing round of over 500 million Chinese yuan (approximately $73 million) led by OrbiMed with participation from Qiming Venture Partners and other investors, per September 3, 2026 disclosure. Proceeds will support continued development of the company's lead candidate zovaglutide (ZT002, a monthly subcutaneous injectable GLP-1 receptor agonist peptide currently in Phase 3 HORIZON-1 trial for weight management in adults with overweight or obesity in China). Phase 2 data at EASD 2025 documented up to 13.8% weight loss at Week 24 with monthly dosing. Zovaglutide is positioned as a potential first-to-market monthly GLP-1 peptide (as opposed to the antibody-peptide conjugate MariTide from Amgen or the lipidated small-molecule approaches at Pfizer/Metsera). The financing extends the H2 2026 obesity-peptide financing wave that has included Parabilis's $670M IPO, Metsera-related asset transitions, and Superluminal's $60M Series B.
Ionis Pharmaceuticals (NASDAQ: IONS) and Royalty Pharma (NASDAQ: RPRX) both issued statements Friday September 4, 2026 following the Novartis pelacarsen Lp(a)HORIZON Phase 3 primary endpoint miss. Ionis, the original developer that licensed pelacarsen to Novartis in 2019, is entitled to potential low-double-digit tiered royalties on future net sales that now appear unlikely absent a resubmission based on a different endpoint or population. Royalty Pharma acquired a portion of Ionis's royalty rights on pelacarsen in a 2019 transaction and had modeled multi-hundred-million-dollar revenue on approval. Both companies emphasized the substantial Lp(a) reduction achieved in the trial and the value of the dataset for the broader Lp(a) research field. The miss lands within days of Ionis's September 3 FDA approval of Zanvastro (zilganersen) for Alexander disease, which provided commercial and pipeline offset. Analyst commentary noted that the Ionis antisense franchise remains strong despite the pelacarsen setback, with Wainua (eplontersen), Zanvastro, and the deep pipeline anchoring the platform.
The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting takes place in Milan September 28 through October 2, 2026, and sets up the largest single September catalyst window for obesity-peptide investor and clinical interest. AstraZeneca will present Phase 2 data on AZD6234 (selective amylin receptor peptide agonist) monotherapy from APRICUS plus the ASCEND Phase 2b combination with AZD9550 GLP-1/glucagon dual agonist. Zealand Pharma and Roche will present petrelintide (amylin analog) data from ZUPREME-2 (obesity plus type 2 diabetes) with the Phase 3 monotherapy program preparing to initiate late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD calendar coincides with the Roche Pharma Day investor event on Monday September 28, 2026 that will update on the top-three-obesity-portfolio (petrelintide, enicepatide, HM17321). Ascendis Pharma is also expected to provide TransCon CNP achondroplasia updates.
Medicus Pharma (NASDAQ: MDCX) announced Wednesday September 2, 2026 a Co-Development and License Agreement with Pfizer (NYSE: PFE) granting Medicus an exclusive, sublicensable, royalty-bearing worldwide license to develop, manufacture, and commercialize PF-08046031 (CD228V, an early clinical-stage antibody-drug conjugate targeting melanotransferrin / CD228). Terms: $12 million upfront cash to Pfizer, an additional $15 million payable on the first anniversary of the effective date, plus up to $1 billion+ in aggregate milestone payments and low-double-digit tiered royalties on future net sales. Pfizer paid Medicus $2 million in development funding restricted to the CD228V program. Medicus retains sole authority and control of development, manufacture, regulatory approval, and commercialization; Pfizer holds review-and-comment rights on development plans and an option to fund development from the first registrational trial. PF-08046031 originated in the Seagen pipeline acquired by Pfizer in December 2023 and represents one of several Seagen-descended assets Pfizer has out-licensed since the acquisition.
Novo Nordisk (NYSE: NVO) commercially launched Wegovy pill (oral semaglutide 25 mg for chronic weight management) in Germany on Tuesday September 1, 2026, the first European market for the once-daily oral obesity formulation after the U.S. launch in January 2026. Wegovy pill was FDA-approved in December 2025 as the first oral GLP-1 receptor agonist for obesity, and has topped 5 million cumulative U.S. prescriptions in the first 8 months per Novo Nordisk H1 2026 disclosures. The German launch positions Wegovy pill against Eli Lilly's Foundayo (orforglipron, small-molecule oral GLP-1) which received FDA approval April 1, 2026 and is preparing for European launch pending EMA review. The oral formulation is intended to address patient-preference research showing that 71% of adults with obesity prefer a daily pill over a weekly injection when taking prescription weight-loss medication. Under the German AMNOG process, national reimbursement negotiation will follow marketing launch over the next 6-12 months.
The Rare Pediatric Disease Priority Review Voucher (PRV) granted to Ionis Pharmaceuticals (NASDAQ: IONS) alongside the Zanvastro (zilganersen) FDA approval Thursday September 3, 2026 for Alexander disease adds substantial commercial value to the launch economics. PRVs have historically sold for $150 to $350 million on the secondary market and can be transferred an unlimited number of times. Recent PRV transactions: Arrowhead Pharmaceuticals sold a PRV for $215 million cash in connection with the plozasiran FCS approval earlier in 2026; other recent PRV sales have priced in the $100-200 million range. Ionis has not yet disclosed plans for the PRV — the company can use it to accelerate FDA review of a future NDA/BLA submission (from standard 10-12 months to priority 6 months) or sell it to another drug developer. The PRV program has faced periodic legislative sunset threats and is currently authorized through December 2026; the incentive continues to drive investment into rare pediatric disease programs where the commercial market alone would not economically justify development.
Typewriter Therapeutics announced Thursday September 3, 2026 its emergence from stealth with $56 million in Series A financing co-led by RA Capital Management and AN Venture Partners, with participation from ANRI, Gemseki, and SBI US Gateway Fund. The proceeds will advance the company's target-primed reverse transcription (TPRT) non-viral gene therapy platform toward clinical development, with initial focus on two high-value indications: in-vivo CAR-T and genetic liver diseases. TPRT uses jumping-gene-inspired biology to insert therapeutic DNA at specific target sites without the packaging-size constraints of AAV vectors or the payload delivery constraints of lipid nanoparticles. Typewriter plans to initiate non-human primate studies in late 2026 and establish its first in-vivo CAR-T development candidate over the next 12 months. The financing continues the H2 2026 in-vivo CAR-T financing wave that also delivered Umoja Biopharma's $100 million+ round and Capstan Therapeutics' Series C earlier in the summer.
Invivyd (NASDAQ: IVVD, Waltham, Massachusetts biopharma focused on serious viral infectious diseases) announced Tuesday September 1, 2026 that the Board of Directors appointed Chairman Marc W. Elia as Chief Executive Officer effective August 30, 2026. Elia has led Invivyd's corporate and scientific strategy since joining the board in 2022 and will serve as Chairman and CEO going forward at an annual base salary of $750,000. The board also named Ajay Royan Lead Independent Director and added Ian Sheffield as an independent director. The leadership transition is timed to Phase 3 readouts for VYD2311, an investigational anti-SARS-CoV-2 monoclonal antibody, in the DECLARATION and LIBERTY studies — both expected in the coming weeks. Invivyd's Pemgarda (pemivibart, the previous-generation SARS-CoV-2 antibody for pre-exposure prophylaxis in immunocompromised adults) received Emergency Use Authorization in March 2024 and remains the company's primary commercial product. A DECLARATION/LIBERTY win would extend the pre-exposure prophylaxis franchise and provide the commercial anchor for a broader antibody-plus-vaccine COVID pipeline.
Eli Lilly (NYSE: LLY) continued rollout through September 2026 of the early-access program for retatrutide (a once-weekly subcutaneous injectable GIP/GLP-1/glucagon triple agonist peptide for obesity) ahead of the Q1 2027 BLA submission plan confirmed after the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 wins in obesity plus type 2 diabetes and obesity plus established cardiovascular disease. The 12 mg retatrutide dose produced 28.3% mean weight loss at 80 weeks in the TRIUMPH-1 Phase 3 obesity monotherapy trial reported in May 2026, the highest weight loss reported for any obesity therapy in a Phase 3 setting. TRIUMPH-4 (knee osteoarthritis, 68 weeks) added 28.7% weight loss plus improvements in pain and physical function. Seven Phase 3 readouts total are expected across the retatrutide program in 2026. Lilly management has framed retatrutide as the successor commercial franchise to Zepbound and Mounjaro, with launch anticipated 2027-2028 under the Most Favored Nation pricing framework that would apply from initial approval per the November 2025 pricing agreement.
Amgen (NASDAQ: AMGN) continued through September 2026 the consolidation of its obesity portfolio around MariTide (maridebart cafraglutide, a monthly subcutaneous injectable antibody-peptide conjugate combining GLP-1 receptor agonist activity via the peptide component with GIP receptor antagonism via the antibody component) following the July 29, 2026 Q2 disclosure that Phase 1 AMG 513 development was halted. Amgen has launched a late-stage program specifically to test whether patients currently on weekly GLP-1 injections can be switched to monthly MariTide with equivalent efficacy and comparable tolerability — a differentiation strategy that uses the monthly dosing convenience as a switch driver rather than a first-line efficacy claim. Amgen expects to file for MariTide regulatory approval in late 2026 to early 2027. Six Phase 3 MariTide trials are enrolling across obesity, type 2 diabetes, heart failure, and obstructive sleep apnea. Cantor Fitzgerald analyst commentary earlier in 2026 had flagged a 4% bone mineral density decline signal from Phase 1 as a concern; Phase 3 data on bone health will factor into commercial positioning.
Simcere Zaiming (a subsidiary of China's Simcere Pharmaceutical Group) announced Wednesday September 2, 2026 an exclusive global licensing agreement with Roche for SIM0660, a T-cell engager tri-specific antibody targeting CD79a, CD19, and CD3 for B-cell-mediated diseases. Deal terms: $75 million upfront plus up to $1.53 billion in total development, regulatory, and commercial milestone payments plus tiered royalties up to double-digits on future net sales. Roche acquires exclusive global rights to develop, manufacture, and commercialize SIM0660. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce T-cell-mediated cytotoxicity while limiting cytokine release, positioned to compete with the emerging poly-specific antibody category (Amgen tarlatamab, Regeneron REGN5459, Janssen amivantamab). The transaction is the latest in a $60+ billion H1 2026 wave of China-to-multinational biotech licensing that continues to feed U.S. and European pharma pipelines.
Analytics firm GlobalData published Wednesday September 2, 2026 a myasthenia gravis (MG) market forecast projecting the seven-major-markets (7MM: United States, France, Germany, Italy, Spain, United Kingdom, Japan) MG treatment market to grow from $4.5 billion in 2024 to $13.0 billion in 2034 at an 11.1% CAGR, driven by launches and label expansions in the anti-FcRn class (argenx Vyvgart Hytrulo, Johnson & Johnson Imaavy nipocalimab), complement inhibitors (Alexion/AstraZeneca Ultomiris, Soliris), and BAFF/BLyS-targeting therapies (Cytokinetics aficamten in adjacent indications). The forecast supports the ongoing peptide-therapeutic case in autoimmune indications where synthetic peptide-vaccine and peptide-immunomodulator approaches (thymalfasin, thymosin analogs) are being evaluated as adjuncts to the biologics-first standard-of-care. Anti-FcRn represents the fastest-growing MG segment given the manageable safety profile and infrequent dosing versus the plasmapheresis and IVIG protocols that dominated the pre-Vyvgart era.
Novartis (NYSE: NVS) shares rose more than 4% Tuesday September 1 and continued climbing Wednesday September 2, 2026 following the twin REMODEL-1 and REMODEL-2 Phase 3 wins of remibrutinib (an oral BTK inhibitor) in relapsing multiple sclerosis, which met both primary endpoints versus teriflunomide with a clean liver-safety profile across the 4,500+ patient program. Investor focus now turns to two additional Novartis growth-vehicle programs: pacibekitug (an anti-IL-6 monoclonal antibody acquired in the $1.4 billion Tourmaline Bio acquisition earlier in 2026) advancing into Phase 3 for cardiovascular risk reduction despite Novo Nordisk's ZEUS ziltivekimab Phase 3 miss at ESC 2026 last weekend; and the ongoing integration of the $12 billion Avidity Biosciences acquisition centered on RNAi drug delivery to muscle tissue for facioscapulohumeral muscular dystrophy, DM1 myotonic dystrophy, and Duchenne muscular dystrophy programs. Novartis Q3 2026 earnings release is scheduled for late October.
GSK (NYSE: GSK) announced Tuesday September 1, 2026 that its mRNA seasonal influenza vaccine candidate will advance to Phase 3 development in September 2026 following positive Phase 2 immunogenicity data presented at the OPTIONS XIII Conference for the Control of Influenza. The vaccine candidate demonstrated higher immune responses against all influenza strains tested compared to licensed standard-dose and high-dose inactivated flu vaccines in both younger and older adults, and was generally well tolerated. Differentiation: GSK's vaccine is the first mRNA flu candidate to advance to Phase 3 designed to target both hemagglutinin (HA) and neuraminidase (NA), the two primary influenza surface antigens; licensed flu vaccines primarily target HA. Growing evidence suggests dual HA-plus-NA targeting could improve protection, illness severity, and transmission reduction. The FDA granted Fast Track designation in July 2026. The advancement sets up direct Phase 3 competition with Moderna's mNEXSPIKE (approved May 2025) and Pfizer's mRNA flu program, extending the mRNA respiratory-vaccine class beyond COVID-19.